Anzeige
Mehr »
Login
Sonntag, 07.03.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Bam Bam Resources und die Mega-Kupferlagerstätte in Teslas Hinterhof!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1T90L ISIN: SE0005162880 Ticker-Symbol: DMN 
Frankfurt
05.03.21
08:02 Uhr
3,335 Euro
+0,035
+1,06 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
DIAMYD MEDICAL AB Chart 1 Jahr
5-Tage-Chart
DIAMYD MEDICAL AB 5-Tage-Chart

Aktuelle News zur DIAMYD MEDICAL Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoUpdate on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd176STOCKHOLM, March 4, 2021 /PRNewswire/ -- The upcoming Phase III trial with Diamyd in new-onset type 1 diabetes will be based on the first precision medicine approach in the field. The...
► Artikel lesen
DIAMYD MEDICAL Aktie jetzt für 0€ handeln
DoDIAMYD MEDICAL AB: Update on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd-
26.02.DIAMYD MEDICAL AB: DIAGNODE-2 results and meta-analysis with Diamyd to be presented at diabetes conference6
22.02.DIAMYD MEDICAL AB: Diamyd Medical makes an investment in MainlyAI3
20.01.DIAMYD MEDICAL AB: Quarterly Report I 20/214
14.01.DIAMYD MEDICAL AB: Positive safety evaluation of Remygen in high dose and in combination with Alprazolam gives the go-ahead for the continuation of the trial2
12.01.DIAMYD MEDICAL AB: Meta-analysis updated with DIAGNODE-2 results provides further support for a precision medicine approach using Diamyd1
22.12.20DIAMYD MEDICAL AB: Annual Report 19/202
19.12.20DIAMYD MEDICAL AB: Immunological analysis of Phase IIb trial with Diamyd show differences between genetically defined patient groups-
18.12.20DIAMYD MEDICAL AB: Board member in Diamyd Medical buys shares from main owner-
16.12.20Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes247STOCKHOLM, Dec. 16, 2020 /PRNewswire/ -- Diamyd Medical and the Critical Path Institute (C-Path) are proud to announce their collaboration to significantly improve the scientific community's...
► Artikel lesen
16.12.20DIAMYD MEDICAL AB: Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes2
03.12.20Diamyd Medical with MainlyAI and KTH awarded VINNOVA funding for AI driven sustainable production236STOCKHOLM, Dec. 3, 2020 /PRNewswire/ -- Diamyd Medical together with MainlyAI AB and KTH Royal Institute of Technology have been awarded funding by the Swedish Governmental Innovation Agency...
► Artikel lesen
03.12.20DIAMYD MEDICAL AB: Diamyd Medical with MainlyAI and KTH awarded VINNOVA funding for AI driven sustainable production2
26.11.20Bulletin from Annual General Meeting of Diamyd Medical AB1
20.11.20DIAMYD MEDICAL AB: Diamyd Medical will fully subscribe for its pro rata share in NextCell Pharma1
13.11.20DIAMYD MEDICAL AB: Previous findings from a clinical trial with Remygen are discussed as part of a lecture on World Diabetes Day-
13.11.20DIAMYD MEDICAL AB: Diamyd Medical will receive additional USD 3.2 million in connection with divestment of Companion Medical1
12.10.20DIAMYD MEDICAL AB: Financial and operational update about the diabetes vaccine Diamyd7
07.10.20DIAMYD MEDICAL AB: Year-End Report 19/204
Seite:  Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2